Duality Biotherapeutics Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
John Zhu
Chief executive officer
CN¥85.6m
Total compensation
| CEO salary percentage | 2.8% |
| CEO tenure | 5.3yrs |
| CEO ownership | 7.6% |
| Management average tenure | 2.9yrs |
| Board average tenure | 2.5yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | CN¥86m | CN¥2m | -CN¥1b |
| Dec 31 2023 | CN¥19m | CN¥2m | -CN¥358m |
Compensation vs Market: John's total compensation ($USD11.77M) is above average for companies of similar size in the Hong Kong market ($USD499.21K).
Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.
CEO
John Zhu (53 yo)
5.3yrs
Tenure
CN¥85,562,000
Compensation
Mr. Zhongyuan Zhu, also known as John, is CEO & Chairman of Duality Biotherapeutics Inc. Mr. Zhu serves as Founder and Chief Executive Officer of Duality Biologics (Shanghai) Co., Ltd. (formerly known as D...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman | no data | CN¥85.56m | 7.61% HK$ 1.4b | |
| Vice President of Finance & Executive Director | no data | CN¥5.35m | no data | |
| Chief Scientific Officer | 3.2yrs | no data | no data | |
| Executive Director of Human Resources & Executive Director | no data | CN¥3.35m | no data | |
| Chief Medical Officer | 2.8yrs | no data | no data | |
| Chief Business Officer | 2.9yrs | no data | no data | |
| Senior VP & Head of Drug Discovery | no data | no data | no data | |
| VP & Head of Regulatory Affairs | no data | no data | no data | |
| Vice President of Development Science | no data | no data | no data | |
| Vice President of Translational Medicine | no data | no data | no data | |
| Vice President of Commercial Strategy | no data | no data | no data | |
| Head of Legal & Compliance and Joint Company Secretary | less than a year | no data | no data |
2.9yrs
Average Tenure
47.5yo
Average Age
Experienced Management: 9606's management team is considered experienced (2.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman | 5.3yrs | CN¥85.56m | 7.61% HK$ 1.4b | |
| Vice President of Finance & Executive Director | 4.1yrs | CN¥5.35m | no data | |
| Executive Director of Human Resources & Executive Director | 4.1yrs | CN¥3.35m | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Non-Executive Director | less than a year | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Chairman of Scientific Advisory Board | no data | no data | no data | |
| Independent Non-Executive Director | less than a year | no data | no data | |
| Non-Executive Director | less than a year | no data | no data | |
| Independent Non-Executive Director | less than a year | no data | no data | |
| Non-Executive Director | 4.1yrs | no data | no data |
2.5yrs
Average Tenure
45.5yo
Average Age
Experienced Board: 9606's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/04 17:12 |
| End of Day Share Price | 2025/05/02 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Duality Biotherapeutics, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.